
CHF-4227
CAS No. 444643-64-5
CHF-4227( —— )
Catalog No. M36146 CAS No. 444643-64-5
CHF-4227 is a novel, potent and selective estrogen receptor modulator that reduces cholesterol and LDL cholesterol concentrations.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 296 | Get Quote |
![]() ![]() |
5MG | 459 | Get Quote |
![]() ![]() |
10MG | 657 | Get Quote |
![]() ![]() |
25MG | 994 | Get Quote |
![]() ![]() |
50MG | 1371 | Get Quote |
![]() ![]() |
100MG | 1773 | Get Quote |
![]() ![]() |
500MG | 3537 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCHF-4227
-
NoteResearch use only, not for human use.
-
Brief DescriptionCHF-4227 is a novel, potent and selective estrogen receptor modulator that reduces cholesterol and LDL cholesterol concentrations.
-
DescriptionCHF-4227 is a novel, potent and selective estrogen receptor modulator that reduces cholesterol and LDL cholesterol concentrations.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorEstrogen Receptor/ERR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number444643-64-5
-
Formula Weight471.59
-
Molecular FormulaC30H33NO4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C1=C(COC=2C1=CC=C(O)C2)C3=CC=C(OC)C=C3)C4=CC=C(OCCN5CCCCC5)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
AC-186
AC-186 is a nonsteroidal estrogen receptor β (ERβ) agonist with different affinities for ERβ and ERα, with an EC50 of 6 nM for ERβ and 5000 nM for ERα. AC-186 has neuroprotective activity and has been used in the study of Parkinson's disease.
-
Norgestrel
Norgestrel is a synthetic progestin commonly used alone or in combination with an estrogen for contraception.
-
Enclomiphene citrate
Enclomiphene citrate((E)-Clomifene, cis-Clomifene, RMI-16289, ICI-46476)?is a nonsteroidal selective estrogen receptor modulator (SERM) that is under development for the treatment of male hypogonadism.